top of page
Pipeline
Pipeline
SirnaMed’s pipeline is led by targeting genes that drive tumor treatment resistance. These tumors are notoriously stubborn, resulting in patients suffering both relapse, and metastasis. We are starting with patients with the most urgent unmet need, because our technology may be one of the few treatment options these patients have.
Colon Cancer
Breast Cancer
siRNA-alone
NHL
NSCLC
CLL
AML
Multiple
Undisclosed
Clinical Development
IND Studies
Lead Optimization
In-vivo Proof-of-Concept
Target ID & Validation
Indication
Target: Xkr8
SMT001
SMT002
SMT003
SMT004
SMT005
SMT006
Target: iRhom1
Target: SERPINB9
Target: mutEGFR
Target: BTK
Target: BCL2
Target: PD-L1
Target: Combo
SMT007
SMT008
Combo
Combo
siRNA-alone
SMT001
xkr8
Colon Cancer
Breast Cancer
iRhom1
SMT002
NHL
SERPINB9
SMT003
NSCLC
mutEGFR
SMT004
CLL
BTK
SMT005
AML
BCL2
SMT006
Multiple
PD-L1
SMT007
Lead Optimization
In-vivo Proof-of-Concept
Target ID & Validation
Indication
Target
Product
IND Studies
Clinical Development
Undisclosed
Combo
SMT008
SirnaMed
Breast Cancer
siRNA-alone
NHL
NSCLC
CLL
AML
Multiple
Clinical Development
IND Studies
Lead Optimization
In-vivo Proof-of-Concept
Target ID & Validation
Indication
Target: Xkr8
SMT001
SMT002
SMT003
SMT004
SMT005
SMT006
Target: iRhom1
Target: SERPINB9
Target: mutEGFR
Target: BTK
Target: BCL2
Target: PD-L1
Target: Combo
SMT008
Combo
Colon Cancer
SMT007
Undisclosed
bottom of page